Sofinnova Investments’s Supernus Pharmaceuticals SUPN Stock Holding History

Sofinnova Investments’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$48.2M	Buy	1,036,328 +82,019	+9%	+$3.94M	2.49%	11
2026 Q1	$49.3M	Buy	954,309 +401,214	+73%	+$20.4M	1.87%	16
2025 Q4	$27.5M	Buy	553,095 +176,029	+47%	+$8.56M	1.19%	30
2025 Q3	$18M	Sell	377,066 -422,187	-53%	-$17M	0.99%	32
2025 Q2	$25.2M	Buy	799,253 +278,575	+54%	+$8.93M	1.54%	21
2025 Q1	$17.1M	Buy	+520,678	New	+$18.5M	1.11%	30
2020 Q4	–	Sell	-330,295	Closed	-$6.88M	–	79
2020 Q3	$6.88M	Sell	330,295 -148,034	-31%	-$3.36M	0.51%	35
2020 Q2	$11.4M	Buy	+478,329	New	+$10.6M	0.72%	32

Other funds holding SUPN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Sofinnova Investments's SUPN Position: Q2 2026 in Review

Sofinnova Investments increased its Supernus Pharmaceuticals (SUPN) stake by 8.6% in Q2 2026, buying an estimated $3.94M and bringing the position to 1,036,328 shares worth $48.2M. The position accounts for 2.49% of the portfolio, ranked #11.

Sofinnova Investments first reported a position in SUPN in Q2 2020 and has held it in 8 quarters since. The position peaked at $49.3M in Q1 2026. 334 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

Sofinnova Investments held 1,036,328 shares of Supernus Pharmaceuticals worth $48.2M as of Q2 2026.
Sofinnova Investments bought 82,019 Supernus Pharmaceuticals shares in Q2 2026, an estimated $3.94M.
Supernus Pharmaceuticals made up 2.49% of Sofinnova Investments's portfolio in Q2 2026, its #11 holding.
Sofinnova Investments first reported a position in Supernus Pharmaceuticals in Q2 2020 and has held it in 8 quarters since.
Sofinnova Investments's Supernus Pharmaceuticals position peaked at $49.3M in Q1 2026.
334 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Sofinnova Investments's 13F filing for Q2 2026, filed 14 Aug 2026.